Change in NRLファーマ's Fiscal Year-End and the Consolidation Period
First written in FY2019-Q1. 4 of 6 entries say "Restated". Latest entry: FY2020.
22 other companies' latest entry also says "Achieved".
- FY2020AchievedAnnual report
「The fiscal year-end of every consolidated subsidiary coincides with the consolidated fiscal year-end.」
Following adjustments to the period included in consolidation due to NRL Pharma's change in fiscal year-end, the fiscal year-end of every consolidated subsidiary came to coincide with the consolidated fiscal year-end. - FY2020-Q2RestatedAnnual report
「Previously, NRL Pharma Co., Ltd., a consolidated subsidiary whose fiscal year-end was 31 March, used financial statements as of that date and made the necessary adjustments for material transactions arising between that date and the consolidated fiscal year-end. From the first quarter of the current consolidated fiscal year, however, it has changed its fiscal year-end to 30 June.」
The accounting treatment for changing NRL Pharma's fiscal year-end from 31 March to 30 June is reconfirmed in the segment information for the second quarter. - FY2019RestatedAnnual report
「In connection with this change in fiscal year-end, the consolidated financial statements for the fiscal year include the 15-month period from 1 April 2018 to 30 June 2019.」
In connection with NRL Pharma's change in fiscal year-end, the final full-year disclosure confirms that the fiscal year includes the 15 months from April 2018 to June 2019. - FY2019-Q3RestatedAnnual report
「In connection with this change in fiscal year-end, the consolidated income statement for the third quarter includes the 12-month period from 1 April 2018 to 31 March 2019.」
In connection with NRL Pharma's change in fiscal year-end, it is reconfirmed that the consolidated income statement for the third quarter includes the 12 months from April 2018 to March 2019. - FY2019-Q2RestatedAnnual report
「In connection with this change in fiscal year-end, the consolidated income statement for the second quarter includes the nine-month period from 1 April 2018 to 31 December 2018. Sales of NRL Pharma Co., Ltd., whose fiscal year-end was changed, were ¥150.553 million for the period from 1 April 2018 to 30 June 2018, operating profit was ¥23.365 million, ordinary profit was ¥26.384 million, and profit before income taxes for the quarter was ¥26.384 million.」
In connection with NRL Pharma's change in fiscal year-end, it is reconfirmed that the consolidated income statement for the second quarter includes the nine months from April to December 2018. - FY2019-Q1First statedAnnual report
「Previously, NRL Pharma Co., Ltd., a consolidated subsidiary whose fiscal year-end was 31 March, used financial statements as of that date and made the necessary adjustments for material transactions arising between that date and the consolidated fiscal year-end. From the first quarter of the current fiscal year, however, it has changed its fiscal year-end to 30 June. In connection with this change, the consolidated income statement for the first quarter includes the six-month period from 1 April 2018 to 30 September 2018.」
NRL Pharma's fiscal year-end was changed from 31 March to 30 June, and the consolidated income statement for the first quarter includes the six months from April to September 2018.